GO:0006527 L-arginine catabolic process: Metabolic Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0006527 (L-arginine catabolic process) describes the chemical reactions and pathways that break down L-arginine into downstream metabolites such as L-ornithine, urea, polyamines, and nitric oxide precursors.
• The pathway is central to nitrogen disposal, immune regulation, and vascular tone, with arginase, nitric oxide synthases (NOS1/NOS2/NOS3), and ornithine decarboxylase (ODC1) as key enzymes.
• L-arginine catabolism modulates T cell metabolism and anti-tumor activity, making it a target in immuno-oncology.
• Dysregulated L-arginine breakdown contributes to diabetic cardiomyopathy, obesity-related metabolic dysfunction, and hypoxia-associated pathology.
• Excessive L-arginine catabolism via the MEK-ERK-NO axis has been linked to myopia development in experimental models.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable precise dissection of each enzymatic step in this pathway.
Description
L-arginine is a semi-essential amino acid that serves as a substrate for multiple competing catabolic enzymes, and its breakdown is captured by the Gene Ontology term GO:0006527, L-arginine catabolic process. This biological process encompasses the chemical reactions and pathways resulting in the degradation of L-arginine, producing metabolites that feed into the urea cycle, polyamine biosynthesis, and nitric oxide signaling. Because L-arginine catabolism intersects with immune cell function, vascular biology, and energy metabolism, it has become a focal point for researchers in immunology, oncology, and metabolic disease. The pathway is not merely a disposal route; it actively shapes cellular microenvironments. For example, arginase-mediated L-arginine depletion in the tumor microenvironment impairs T cell proliferation and effector function, while nitric oxide synthase (NOS) activity generates nitric oxide that influences vasodilation and inflammation. In obesity and diabetes, altered L-arginine catabolism contributes to endothelial dysfunction and insulin resistance. These findings underscore why GO:0006527 is a high-value annotation for functional genomics and therapeutic target discovery. Understanding the enzymes, transporters, and regulatory nodes of L-arginine catabolism enables researchers to design CRISPR-based models that test causality. Knockout of arginase or NOS isoforms, point mutations that alter catalytic activity, and knock-in reporters that track flux are all tractable strategies for dissecting this pathway in disease contexts.
L-arginine catabolic process At A Glance
| GO ID | GO:0006527 |
|---|---|
| GO term | L-arginine catabolic process |
| Ontology | biological_process |
| Synonym | arginine breakdown; arginine catabolism; arginine degradation |
| Major function | Breakdown of L-arginine into L-ornithine, urea, nitric oxide precursors, and polyamines |
| Key enzymes | ARG1, ARG2, NOS1, NOS2, NOS3, ODC1, ADC |
| Subcellular locations | Cytosol, mitochondria, peroxisomes |
| Related pathways | Urea cycle, polyamine biosynthesis, nitric oxide signaling |
| Disease relevance | Cancer, diabetic cardiomyopathy, obesity, myopia, hypoxia-associated conditions |
What Is GO:0006527?
GO:0006527, L-arginine catabolic process, is defined by QuickGO as the chemical reactions and pathways resulting in the breakdown of L-arginine. In practical terms, it includes enzymatic steps that convert L-arginine into L-ornithine and urea via arginase, into citrulline and nitric oxide via nitric oxide synthases, and into agmatine or polyamines via decarboxylation and downstream reactions. The term is a biological process annotation and is synonymous with arginine breakdown, arginine catabolism, and arginine degradation.
Why Is L-arginine catabolic process Important in Cell Biology?
L-arginine catabolic process is important because it controls the availability of L-arginine for protein synthesis and immune signaling while generating bioactive molecules such as nitric oxide and polyamines. This pathway influences T cell survival and anti-tumor immunity, vascular tone, and metabolic homeostasis, and its dysregulation is implicated in cancer, diabetes, and cardiovascular disease. Consequently, GO:0006527 is a key annotation for researchers studying immunometabolism, endothelial function, and therapeutic resistance.
• Regulates T cell metabolism and survival, affecting anti-tumor immunity.
• Produces nitric oxide, a critical vasodilator and signaling molecule.
• Supplies L-ornithine for polyamine synthesis, supporting cell proliferation.
• Contributes to urea cycle function and nitrogen disposal.
• Linked to diabetic cardiomyopathy and endothelial dysfunction.
• Modulates glucose and lipid metabolism in obesity and diabetes.
• Involved in hypoxia adaptation and clinical conditions associated with low oxygen.
• Excessive activity via MEK-ERK-NO signaling is associated with myopia.
• Provides biomarkers and therapeutic targets in oncology.
• Enables CRISPR-based functional studies of metabolic enzymes.
What Happens During L-arginine catabolic process?
Hydrolysis by Arginase
In simple terms: Arginase cuts L-arginine into L-ornithine and urea.
The first major route of L-arginine catabolism is hydrolysis catalyzed by arginase isoforms ARG1 (cytosolic) and ARG2 (mitochondrial), yielding L-ornithine and urea. This reaction is a central node because L-ornithine feeds into polyamine biosynthesis and the urea cycle, while urea is excreted as a nitrogen waste product. In immune cells, arginase-mediated L-arginine depletion can suppress T cell responses, a mechanism exploited by tumors.
Oxidation by Nitric Oxide Synthases
In simple terms: NOS enzymes convert L-arginine into nitric oxide and citrulline.
Nitric oxide synthases (NOS1, NOS2, NOS3) oxidize L-arginine to L-citrulline and nitric oxide, a gaseous signaling molecule. This branch is critical for vascular tone, neurotransmission, and immune defense. In diabetes, uncoupling of NOS and altered L-arginine availability can reduce nitric oxide bioavailability, contributing to endothelial dysfunction. The MEK-ERK-NO signaling axis has also been implicated in myopia development when L-arginine is supplemented excessively.
Decarboxylation and Polyamine Synthesis
In simple terms: L-arginine can be converted into agmatine and then into polyamines.
Arginine decarboxylase (ADC) converts L-arginine to agmatine, which can be further metabolized to putrescine and higher polyamines. Alternatively, L-ornithine produced by arginase is decarboxylated by ODC1 to putrescine, a precursor for spermidine and spermine. Polyamines are essential for cell proliferation and differentiation, linking L-arginine catabolism to growth control and cancer.
Integration with the Urea Cycle
In simple terms: The breakdown products enter the urea cycle to dispose of nitrogen.
L-ornithine generated by arginase re-enters the urea cycle, where it is converted to citrulline and eventually back to arginine, completing a cycle that detoxifies ammonia. This integration means that L-arginine catabolic process is not linear but part of a metabolic loop that balances nitrogen intake and excretion. Defects in this loop can lead to hyperammonemia and related metabolic disorders.
Regulation by Substrate Availability and Enzymes
In simple terms: The pathway is controlled by how much L-arginine is available and which enzymes are active.
L-arginine catabolism is regulated by substrate availability, enzyme expression, and post-translational modifications. For example, L-arginine supplementation can modulate T cell metabolism and enhance survival and anti-tumor activity. In obesity and diabetes, altered L-arginine metabolism affects glucose and lipid homeostasis. Hypoxia can also shift L-arginine utilization, with clinical implications for conditions associated with low oxygen.
Key Genes Involved in GO:0006527 L-arginine catabolic process
The following genes encode enzymes and transporters that directly participate in or regulate L-arginine catabolic process.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ARG1 | Cytosolic arginase that hydrolyzes L-arginine to L-ornithine and urea | Target in cancer immunology and T cell suppression |
| ARG2 | Mitochondrial arginase with similar catalytic activity | Linked to vascular and metabolic regulation |
| NOS1 | Neuronal nitric oxide synthase producing NO from L-arginine | Implicated in neurotransmission and hypoxia responses |
| NOS2 | Inducible nitric oxide synthase in immune cells | Key in inflammation and anti-tumor immunity |
| NOS3 | Endothelial nitric oxide synthase regulating vascular tone | Central to diabetic endothelial dysfunction |
| ODC1 | Ornithine decarboxylase converting L-ornithine to putrescine | Drives polyamine synthesis and cell proliferation |
| ADC | Arginine decarboxylase producing agmatine | Less studied but relevant to polyamine flux |
| SLC7A1 | Cationic amino acid transporter for L-arginine uptake | Affects substrate availability for catabolism |
| SLC7A2 | L-arginine transporter in macrophages | Modulates immune cell arginine availability |
| ASS1 | Argininosuccinate synthase in the urea cycle | Connects L-arginine catabolism to nitrogen disposal |
| ASL | Argininosuccinate lyase regenerating L-arginine | Part of the urea cycle loop |
| OTC | Ornithine transcarbamylase in the urea cycle | Links L-ornithine to ammonia detoxification |
| CPS1 | Carbamoyl phosphate synthetase 1 | Urea cycle entry point for nitrogen |
| GATM | Glycine amidinotransferase using L-arginine | Competes for L-arginine for creatine synthesis |
| PRMT1 | Protein arginine methyltransferase consuming L-arginine | Competes with catabolic enzymes |
| DDAH1 | Dimethylarginine dimethylaminohydrolase regulating ADMA | Modulates NOS activity and L-arginine availability |
| GCH1 | GTP cyclohydrolase 1 for tetrahydrobiopterin synthesis | Cofactor supply for NOS |
How Is L-arginine catabolic process Regulated?
L-arginine catabolic process is regulated at multiple levels. Substrate availability is controlled by transporters such as SLC7A1 and SLC7A2, and by dietary L-arginine intake. Enzyme expression is induced by inflammatory cytokines (e.g., NOS2) or suppressed by metabolic cues. Cofactor availability, particularly tetrahydrobiopterin (BH4) synthesized via GCH1, determines whether NOS enzymes produce nitric oxide or become uncoupled. In T cells, L-arginine levels modulate metabolic fitness and survival, linking nutrient sensing to immune function. In obesity and diabetes, hormonal and inflammatory signals alter arginase and NOS activity, shifting the balance between catabolic branches. Hypoxia also influences L-arginine metabolism, with therapeutic implications.
L-arginine catabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ARG1 | Cancer immune evasion | ARG1 knockout in tumor cells or T cells |
| NOS2 | Inflammatory and anti-tumor immunity | NOS2 knockout macrophages |
| NOS3 | Diabetic endothelial dysfunction | NOS3 point mutation or knockout in endothelial cells |
| ODC1 | Cell proliferation and polyamine flux | ODC1 overexpression or knockout |
| ADC | Polyamine metabolism | ADC knockout in relevant cell lines |
Cancer and Immunometabolism
Tumors often upregulate arginase or NOS2 to deplete L-arginine in the microenvironment, impairing T cell proliferation and effector function. This metabolic checkpoint supports immune evasion and is a target for immunotherapy. L-arginine supplementation can enhance T cell survival and anti-tumor activity in preclinical models.
Diabetic Cardiomyopathy and Vascular Disease
Altered L-arginine catabolism contributes to diabetic cardiomyopathy through reduced nitric oxide bioavailability and increased oxidative stress. Endothelial NOS uncoupling and arginase activation are implicated in endothelial dysfunction, making this pathway a therapeutic target.
Obesity and Metabolic Syndrome
L-arginine modulates glucose and lipid metabolism in obesity and diabetes, and its catabolic enzymes influence insulin sensitivity and adiposity. Dysregulated arginine breakdown can exacerbate metabolic inflammation.
Myopia and Ocular Growth
Excessive L-arginine supplementation has been shown to induce myopia via the MEK-ERK-NO signaling pathway in experimental models, linking L-arginine catabolism to ocular development.
From L-arginine catabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does ARG1 loss enhance T cell anti-tumor activity? | ARG1 knockout in cancer or immune cells |
| Does NOS3 uncoupling contribute to diabetic cardiomyopathy? | NOS3 point mutation or knockout in cardiomyocytes |
| How does L-arginine supplementation affect myopia? | MEK-ERK-NO pathway knock-in reporter in ocular cells |
| What is the role of ODC1 in polyamine synthesis? | ODC1 overexpression and knockout |
| Does hypoxia alter L-arginine catabolic flux? | Hypoxia-inducible factor (HIF) knockout or reporter models |
| Can L-arginine metabolism be tracked in live cells? | Tagged knock-in of ARG1 or NOS2 with fluorescent reporter |
How to Study the L-arginine catabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Stable isotope tracing | Flux through catabolic branches | Quantifying arginase vs NOS activity |
| RNA-seq | Transcript levels of pathway genes | Expression profiling in disease models |
| Western blot | Protein abundance and modifications | Validating knockout or overexpression |
| Immunofluorescence | Subcellular localization | Tracking ARG1/NOS2 in cells |
| Nitric oxide detection | NO production | Assessing NOS activity |
| Polyamine quantification | Putrescine, spermidine, spermine levels | Measuring ODC1 activity |
| CRISPR screening | Gene essentiality and pathway interactions | Identifying modifiers of L-arginine catabolism |
| Metabolomics | Global metabolite changes | Discovering downstream effects |
Metabolic Flux Analysis
Stable isotope tracing with 13C/15N-labeled L-arginine combined with mass spectrometry quantifies flux through arginase, NOS, and polyamine branches. This method reveals how genetic perturbations alter pathway activity.
Gene Expression Profiling
RNA-seq and qPCR measure expression of ARG1, ARG2, NOS1/2/3, ODC1, and transporters under different conditions, providing insight into transcriptional regulation of L-arginine catabolism.
Protein and Post-translational Analysis
Western blotting, immunoprecipitation, and phosphoproteomics assess enzyme abundance and modifications, such as phosphorylation of NOS isoforms, that regulate catalytic activity.
Functional Imaging and Reporter Assays
Fluorescent reporters for nitric oxide (e.g., DAF-FM) and polyamines enable live-cell imaging of L-arginine catabolic products, while knock-in tagged enzymes allow subcellular localization studies.
How CRISPR Can Be Used to Study GO:0006527 L-arginine catabolic process
Knockout
CRISPR knockout of ARG1, ARG2, NOS1/2/3, or ODC1 eliminates specific enzymatic activities, allowing researchers to test their contribution to L-arginine catabolism and disease phenotypes. For example, ARG1 knockout in tumor cells can reverse T cell suppression.
Point Mutation
Point mutations that alter catalytic residues or regulatory phosphorylation sites in NOS3 or ARG1 can dissect enzyme-specific functions without eliminating protein expression. This is useful for separating nitric oxide production from other NOS activities.
Knock-in
Knock-in of fluorescent or affinity tags into endogenous ARG1, NOS2, or ODC1 loci enables real-time tracking of enzyme localization and interaction partners under physiological conditions.
Overexpression
Overexpression of L-arginine catabolic enzymes or transporters can model gain-of-function states observed in cancer or metabolic disease, helping to establish causality.
How EDITGENE Supports L-arginine catabolic process Research
Researchers studying L-arginine catabolic process-related genes often need to determine whether a candidate gene is causally involved in pathway regulation or disease progression. EDITGENE provides CRISPR-based cell model services that enable precise genetic perturbations, from knockout to knock-in, to support mechanistic studies and target validation.
Contact EDITGENE today to design your custom CRISPR model for L-arginine catabolic process research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| NOS3 Knockout HEK293 Cell Line | EDJ-KQ840 | Human | 4846 | Details Get a Quote |
| NOS1 Knockout HEK293 Cell Line | EDJ-KQ844 | Human | 4842 | Details Get a Quote |
| NOS2 Knockout HEK293 Cell Line | EDJ-KQ1428 | Human | 4843 | Details Get a Quote |
| ARG1 Knockout HEK293 Cell Line | EDJ-KQ4083 | Human | 383 | Details Get a Quote |
| OAT Knockout HEK293 Cell Line | EDJ-KQ5371 | Human | 4942 | Details Get a Quote |
| DDAH1 Knockout HEK293 Cell Line | EDJ-KQ8075 | Human | 23576 | Details Get a Quote |
| NOS3 Knockout HCT 116 Cell Line | EDJ-KQ19625 | Human | 4846 | Details Get a Quote |
| OAT Knockout A-549 Cell Line | EDJ-KQ28501 | Human | 4942 | Details Get a Quote |
| OAT Knockout HCT 116 Cell Line | EDJ-KQ28502 | Human | 4942 | Details Get a Quote |
| OAT Knockout HeLa Cell Line | EDJ-KQ28503 | Human | 4942 | Details Get a Quote |
| DDAH1 Knockout A-549 Cell Line | EDJ-KQ33905 | Human | 23576 | Details Get a Quote |
| DDAH1 Knockout HCT 116 Cell Line | EDJ-KQ33906 | Human | 23576 | Details Get a Quote |
| DDAH1 Knockout HeLa Cell Line | EDJ-KQ33907 | Human | 23576 | Details Get a Quote |
| ARG1 Knockout HeLa Cell Line | EDJ-KQ52653 | Human | 383 | Details Get a Quote |
| NOS1 Knockout HeLa Cell Line | EDJ-KQ54004 | Human | 4842 | Details Get a Quote |
Displaying Records 1 To 15 Of 24 Records
Frequently Asked Questions About L-arginine catabolic process
What is L-arginine catabolic process?
It is the biological process defined by GO:0006527 that describes the chemical reactions and pathways resulting in the breakdown of L-arginine into metabolites such as L-ornithine, urea, nitric oxide precursors, and polyamines.
What genes are involved in L-arginine catabolic process?
Key genes include ARG1, ARG2, NOS1, NOS2, NOS3, ODC1, ADC, and transporters such as SLC7A1 and SLC7A2.
What is the GO ID for L-arginine catabolic process?
The GO ID is GO:0006527, a biological process term in the Gene Ontology.
How does L-arginine catabolism affect T cells?
L-arginine catabolism can deplete L-arginine in the microenvironment, impairing T cell proliferation and effector function, while supplementation can enhance T cell survival and anti-tumor activity.
What enzymes break down L-arginine?
Arginase (ARG1, ARG2) hydrolyzes L-arginine to L-ornithine and urea, while nitric oxide synthases (NOS1, NOS2, NOS3) oxidize it to citrulline and nitric oxide.
Is L-arginine catabolism linked to diabetes?
Yes, altered L-arginine catabolism contributes to diabetic cardiomyopathy and endothelial dysfunction, and it modulates glucose and lipid metabolism in obesity and diabetes.
Can CRISPR be used to study L-arginine catabolic process?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models allow precise dissection of each enzymatic step and its role in disease.
What diseases are associated with L-arginine catabolic process?
Cancer, diabetic cardiomyopathy, obesity, myopia, and hypoxia-associated conditions have been linked to this pathway.
How is L-arginine catabolism regulated?
It is regulated by substrate availability, enzyme expression, cofactor supply (e.g., BH4), and post-translational modifications, with crosstalk to immune and metabolic signaling.
What methods study L-arginine catabolic process?
Stable isotope tracing, RNA-seq, Western blot, immunofluorescence, nitric oxide detection, polyamine quantification, CRISPR screening, and metabolomics are commonly used.
Conclusion
GO:0006527 L-arginine catabolic process is a central metabolic pathway that controls nitrogen disposal, immune function, vascular tone, and cell proliferation through the coordinated action of arginases, nitric oxide synthases, and polyamine-synthesizing enzymes. Its dysregulation is implicated in cancer, diabetes, cardiovascular disease, and ocular disorders, making it a rich area for therapeutic target discovery. CRISPR-based cell models provide a robust toolkit to dissect the causal roles of individual genes in this pathway and to accelerate translational research.
References
- 1. Geiger R et al.. 2016. L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity.. Cell 167(3):829-842.e13 PMID: 27745970
- 2. Bao B et al.. 2024. Excessive Supplement of l-Arginine Induces Myopia via Orchestrating the MEK-ERK-NO Signaling Pathway.. J Agric Food Chem 72(47):26462-26474 PMID: 39535109
- 3. Tan H et al.. 2025. Microneedles Loaded with Nitric-Oxide Driven Nanomotors Improve Force-Induced Efferocytosis Impairment and Sterile Inflammation by Revitalizing Macrophage Energy Metabolism.. ACS Nano 19(9):9390-9411 PMID: 40025734
- 4. Thakur MR et al.. 2025. l-Arginine: A multifaceted regulator of diabetic cardiomyopathy.. Biochem Biophys Res Commun 761:151720 PMID: 40186920
- 5. Kurhaluk N. 2023. The Effectiveness of L-arginine in Clinical Conditions Associated with Hypoxia.. Int J Mol Sci 24(9) PMID: 37175912
- 6. Hu S et al.. 2017. L-Arginine Modulates Glucose and Lipid Metabolism in Obesity and Diabetes.. Curr Protein Pept Sci 18(6):599-608 PMID: 27356939
- 7. Szefel J et al.. 2019. Metabolic pathways of L-arginine and therapeutic consequences in tumors.. Adv Med Sci 64(1):104-110 PMID: 30605863
- 8. Hoang HH et al.. 2013. L-arginine, tetrahydrobiopterin, nitric oxide and diabetes.. Curr Opin Clin Nutr Metab Care 16(1):76-82 PMID: 23164986
